Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Epithelial cell states distinguish between uterine cancers
Fri December 3rd - Two epithelial cell states have been identified that can help to distinguish between types of uterine cancer, British researchers announced last night. More
COVID-19 boosters increase immunity
Fri December 3rd - Six different types of COVID-19 boosters are safe and increase immunity following vaccination with either the AstraZeneca or Pfizer-BioNTech jabs, British researchers report today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Vaccine success evidence as lockdown eased

Monday March 29th 2021

Vaccination is proving highly effective in preventing deaths and infection in the UK, according to a series of studies released as lockdown restrictions are relaxed in England.

The UK government said 30 million people have now received vaccines.

Vaccination against COVID-19 has already prevented more than 6,000 deaths in the elderly population, according to one new analysis.

Public Health England estimated the figure by modelling the number of deaths that would have been expected until the end of February.

Its calculations correlate death rates with the anticipated point of vaccine effectiveness, 31 days after vaccination.

It was able to link vaccination to 5,900 deaths prevented in those over the age of 800 and 200 among the over 70s.

A separate analysis by Warwick University concluded that 6,600 deaths in all age groups were prevented until the end of February – as vaccination countered the effect of the new variants of the virus in extending the third wave of the pandemic in the UK.

Dr Mary Ramsay, from Public Health England, said: “This new analysis calculates how many lives they have saved in the first few months of the vaccine programme, and with every additional day more lives have and will be saved. The vaccines have an excellent safety record and I would encourage anyone who is offered a vaccine to take it as soon as possible.

“While the vaccines have a striking impact on mortality, we don’t yet know how much these vaccines will reduce the risk of you passing COVID-19 onto others. Even if you have been vaccinated, it is really important that you continue to act like you have the virus, practise good hand hygiene and stay at home.

“If future evidence shows that vaccines do help to reduce transmission, then it is likely that an even higher number of deaths will have been prevented.

“The true value of these vaccines may also be in terms of future deaths avoided, should there be resurgence of COVID-19 in the UK in the future. Older age presents the single greatest risk of death from COVID-19 – prioritisation of the COVID-19 vaccination programme has focused primarily on an aged-based strategy in order to prevent the greatest loss of life possible.”

* A second study, involving healthcare workers, has shown “strong immune response” after vaccination with the Pfizer mRNA vaccine.

Researchers from the universities of Sheffield and Oxford tested 237 workers for antibody and T-cell responses – and found “robust” responses in 99%.

Researcher Dr Thushan de Silva said: “Our results demonstrate that T cell and antibody responses induced by natural infection are boosted significantly by a single dose of vaccine. While the response to a single dose was lower in infection-naïve individuals, it was still equivalent or better than the immunity in previously infected individuals before it is boosted by vaccination.”

* A third study, published today, finds a 62% reduction in infections among care home residents after a single dose of either vaccine deployed in the UK, five weeks after vaccination.

Researchers at University College London studied outcomes for more than 10,000 residents between December and mid-March.

Researcher Dr Laura Shallcross said: “Our findings show that a single dose has a protective effect that persists from four weeks to at least seven weeks after vaccination. Vaccination reduces the total number of people who get infected, and analysis of lab samples suggests that care home residents who are infected after having the vaccine may also be less likely to transmit the virus.

“We can also infer that the vaccines protect against the highly transmissible UK variant, as this was prevalent during the study period.”

Chief medical officer Professor Chris Whitty said: “These data add to the growing evidence that vaccines are reducing Covid-19 infections and doing so in vulnerable and older populations, where it is most important that we provide as much protection from Covid as possible.”

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long Term Care Facilities (VIVALDI study). medRxiv 29 March 2021

Tags: Elderly Health | Flu & Viruses | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)